Liver transplant: what is left after the viruses

Size: px
Start display at page:

Download "Liver transplant: what is left after the viruses"

Transcription

1 Riunione Monotematica A.I.S.F The Future of Liver Disease: Beyond HCV is there a Role for Hepatologist? Milan 15 th 2016 Liver transplant: what is left after the viruses Stefano Ginanni Corradini Liver Transplant Unit Sapienza Università di Roma stefano.corradini@uniroma1.it

2 Stefano Ginanni Corradini TITOLO:Liver transplant:what is left after the viruses Università Sapienza di Roma Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione e che la presentazione non contiene farmaci in studio o ad uso off-label

3 What is left after the viruses in the liver transplant field? (the role of transplant hepatologists) no fear of post-transplant viral recurrence how will the spared donors be used to transplant more patients with other end-stage liver diseases? will a subgroup of HCV eradicated patients (other than alcoholics) still deserve a liver transplant? how will the spared donors ameliorate the ITT (including access to transplant) outcomes of liver transplantation?

4 Liver transplant activity in Europe over time Viral Crypto/Others Alcoholic

5 Waitlist registrations for NASH and ALD increased over time UNOS DATABASE, new liver transplant waitlist registrants NASH category = diagnosis of NASH + obese (body mass index >30 kg/m2) patients with cryptogenic cirrhosis (CC) NASH, as defined in the study, demonstrated a 170% increase in prevalence from 804 in 2004 to 2174 in 2013 among new liver transplant waitlist registrants NASH Alcoholic Gastroenterology 2015;148:

6 Obese cirrhotic patient outcomes after liver transplantation World J Hepatol 2015;7:

7 Obese cirrhotic patient overall survival after liver transplantation Limitations: o significant heterogeneity (not unexpected given the use of non-randomized studies utilized) o potential confounding variables (differences in immunosuppression, surgical skills, post operative care) Subset analysis that corrected for BMI based on the degree of ascites. The adjusted BMI was not independently predictive of poor patient survival Liver International 2015;35:164-70

8 Obese cirrhotic patient outcomes after liver transplantation Morbid obese patients have worse short-term outcomes The more recent trend in better outcomes may reflect better patient selection (comorbidities!) and improved care More long-term data looking at 5 years and beyond are needed World J Hepatol 2015;7:

9 Diabetes comorbid with obesity is associated with poor survival after liver transplantation Multicenter (Australia and New Zealand; n=617) Dry body mass index was calculated following adjustment for ascites Concomitant diabetes and obesity but not each condition in the absence of the other is associated with reduced post-liver transplant survival. Journal of Gastroenterology and Hepatology 2016;31:

10 Future challenges for Transplant Hepatologists: sarcopenia, sarcopenic obesity and bariatric surgery Future challenges for Transplant Hepatologists: obesity diabetes hypertension hyperlipidaemia cardiovascular disease sarcopenia Sarcopenic obesity is a known risk factor for mortality in cirrhotic patients Sarcopenia is a known risk factor for poor outcomes after liver transplantation What about the effect of sarcopenic obesity on liver transplant outcomes? Timing of sleeve gastrectomy (SG): 1. pretransplant SG (cirrhosis severity, adhesion between the staple line of the stomach and the left lobe of the liver) 2. combined liver transplant and SG (LTSG) 3. SG in the posttransplant setting (immunosuppression, late beneficial effects of surgery) Unknown long-term effect of SG on sarcopenia [Mastino D et al. Obes Surg 2016 Feb 29]

11 Nonalcoholic Steatohepatitis Is the Most Rapidly Growing Indication for Liver Transplantation in Patients With Hepatocellular Carcinoma in the U.S HEPATOLOGY 2014;59:

12 HCC in NAFLD patients has different characteristics then in HCV positive patients multicenter observational prospective study of NAFLD-related HCC (NAFLD-HCC; n=145) vs hepatitis C virus (HCV)-related HCC (n=611) enrolled in secondary care Italian centers Compared to HCV, HCC in NAFLD patients had: a larger volume more often an infiltrative pattern was detected outside specific surveillance Cirrhosis was present in only about 50% of NAFLD-HCC patients, in contrast to the near totality of HCV-HCC. HEPATOLOGY, 2016;63:

13 What is left after the viruses in the liver transplant field? (the role of transplant hepatologists) no fear of post-transplant viral recurrence how will the spared donors be used to transplant more patients with other end-stage liver diseases? will a subgroup of HCV eradicated patients (other than alcoholics) still deserve a liver transplant? how will the spared donors ameliorate the ITT (including access to transplant) outcomes of liver transplantation?

14 Residual risk of hepatocellular carcinoma after HCV eradication In 2030 projected eradication of HCV-related disease in Italy Immunological changes (in some patients)? Future Microbiol.(2015) 10(6),

15 Residual indications to liver transplantation after HCV eradication HCC Cirrhosis progression due to comorbidities: obesity diabetes Late mortality in 1/3 of HCV eradicated cirrhotics

16 Many severely obese transplanted patients were HCV positive and diabetics UNOS DATABASE, adult liver transplants perfomed between 2002 and 2011 All time prevalence of obesity in US liver transplanted pts was 33.1% LIVER TRANSPLANTATION 21: , 2015

17 BMI distribution in HCV-related chronic hepatitis and non-ascitic cirrhotic out-patients at «Sapienza University» according to era 100% 90% 80% 17% 29% 9% 70% 60% 50% 40% 30% % 10% 0% Cirrhotics Cirrhotics Chronic hepatitis S Ginanni Corradini unpublished data

18 Prevalence of diabetes in HCV-related cirrhosis and chronic hepatitis outpatients at «Sapienza University» according to era 100% 6% 90% 80% 29% 26% 70% 60% 50% 40% Diabetics Non-diabetics 30% 20% 10% 0% Cirrhotics Cirrhotics Chronic hepatitis S Ginanni Corradini unpublished data

19 Curing HCV results in a reduced incidence of T2DM, and an improvement of T2DM-related clinical outcomes is possible in diabetic CHC patients who obtain SVR. However, a definite verdict is not possible The high therapeutic efficacy of novel antivirals will ensure that a large number of diabetic cirrhotic patients will achieve eradication; this will enable us to understand the relative contribution of the virus and of lifestyle (and genetics) on T2DM outcome. Meanwhile, we can hypothesise that only early diagnosis and treatment of HCV infection might be associated with regression of T2DM-related clinical manifestations and complications

20 What is left after the viruses in the liver transplant field? (the role of transplant hepatologists) no fear of post-transplant viral recurrence how will the spared donors be used to transplant more patients with other end-stage liver diseases? will a subgroup of HCV eradicated patients (other than alcoholics) still deserve a liver transplant? how will the spared donors ameliorate the ITT (including access to transplant) outcomes of liver transplantation?

21 Time dependent projections of the effect of dual (IFN+RIBA) or triple (IFN+RIBA+Telaprevir or Boceprevir for genotype 1) HCV therapy on liver transplant waiting list satisfaction for patients with HCV-related disease in France Listed no treatment HCC Listed no treatment Decompensated cirrhosis Listed dual and triple therapy Listed dual and triple therapy Transplants performed Transplants perfomed Digestive and Liver Disease 46 (2014)

22 Time dependent projections of the effect of dual (IFN+RIBA) or triple (IFN+RIBA+Telaprevir or Boceprevir for genotype 1) and DAAs (from 2015) HCV therapy on liver transplant waiting list satisfaction for patients with HCV-related disease in France HCC Decompensated cirrhosis Listed dual and triple therapy Listed DAAs Listed dual and triple therapy Transplants performed Transplants performed Listed DAAs Digestive and Liver Disease 46 (2014)

23 In Italy HCV eradication should allow to spare approximately donors per year Viral 37% Viral 60% [HCV=46%; HBV=18%] Liver Match DLD 2011;43:

24 Waitlist mortality and drop-outs are higher in France than in Italy Digestive and Liver Disease 46 (2014)

25 Conclusions The bulk of potential candidates to liver transplantation affected by obesity and/or diabetes (including also an unknown fraction of HCV eradicated) and/or sarcopenia is expected to rapidly increase in the next future These patients should be referred to a liver transplant center as early as possible (even in the pre-cirrhotic stage when obesity is severe/morbid) Transplant hepatologists should strictly interact with nutritionists and endocrinologists In the next years the tesoretto of liver donors spared from transplanting viral patients will allow to ameliorate the ITT outcomes of liver transplantation, provided that all patients have the same chances to be evaluated by transplant centers

Alcoholic Liver Disease as First Indication

Alcoholic Liver Disease as First Indication Alcoholic Liver Disease as First Indication Patrizia Burra Multivisceral Transplant Unit Gastroenterology Department of Surgery, Oncology and Gastroenterology Padua University Hospital, Padua, Italy Patrizia

More information

Pazienti con Genotipo 1 e Cirrosi Scompensata, pre-/post-olt

Pazienti con Genotipo 1 e Cirrosi Scompensata, pre-/post-olt Monotematica AISF 2013 Pazienti con Genotipo 1 e Cirrosi Scompensata, pre-/post-olt Pietro Andreone Dipartimento di Scienze Mediche e Chirurgiche Alma Mater Studiorum, Università di Bologna Pisa, 17-19

More information

Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion

Diagnostic Procedures. Measurement of Hepatic venous pressure in management of cirrhosis. Clinician s opinion 5 th AISF Post-Meeting Course Diagnostic and Therapeutic Invasive Procedures in Hepatology Rome, February 25 th Diagnostic Procedures Measurement of Hepatic venous pressure in management of cirrhosis Clinician

More information

Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine

Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Pierluigi Toniutto Clinica di Medicina Interna Azienda Ospedaliero Universitaria Udine Il sottoscritto dichiara di non aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione

More information

Colangiocarcinoma on the rise!

Colangiocarcinoma on the rise! Colangiocarcinoma on the rise! D. ALVARO, Univ. Sapienza, Rome, Italy. MONOTEMATICA AISF, The future of Liver Diseases, Milano 13-15 Ottobre 2016 Domenico ALVARO, MD. SAPIENZA, ROMA Il sottoscritto dichiara

More information

Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia

Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia Filippo Schepis, MD Università degli Studi di Modena e Reggio Emilia Il sottoscritto dichiara di non aver avuto/di aver avuto negli ultimi 12 mesi conflitto d interesse in relazione a questa presentazione

More information

Role of Nutritional Support in the Treatment of Alcoholic Liver Disease

Role of Nutritional Support in the Treatment of Alcoholic Liver Disease Riunione Monotematica AISF Alcoholic Liver Disease: The New Challenge Roma, 4-6 Ottobre 2017 Role of Nutritional Support in the Treatment of Alcoholic Liver Disease Esmeralda Capristo Divisione di Patologie

More information

Hepatocellular carcinoma: Intra-arterial treatments

Hepatocellular carcinoma: Intra-arterial treatments Hepatocellular carcinoma: Intra-arterial treatments Irene Bargellini U.O. Radiologia Interventistica Azienda Ospedaliero Universitaria Pisana IRENE BARGELLINI,MD UO RADIOLOGIA INTERVENTISTICA, AZIENDA

More information

Hepatocellular carcinoma

Hepatocellular carcinoma Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular

More information

Invasive Evaluation of Portal Hypertension. Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan

Invasive Evaluation of Portal Hypertension. Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan Invasive Evaluation of Portal Hypertension Vincenzo La Mura, MD PhD Department of Biomedical Sciences for Health University of Milan Vincenzo La Mura, MD, PhD Dipartimento di scienze Biomediche per la

More information

6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare

6 Riunione Monotematica A.I.S.F NASH malattia epatica, oncologica e cardiovascolare 6 Riunione Monotematica A.I.S.F. 2015 NASH malattia epatica, oncologica e cardiovascolare Modena, 9 ottobre 2015 Massimo Colombo NAFLD e HCC: caratteristiche distintive Chairman Department of Liver, Kidney,

More information

Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood

Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood RIUNIONE MONOTEMATICA AISF 2013 Personalizzazione della Cura in Epatologia 17-19 ottobre 2013, PISA Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood La sottoscritta dichiara di

More information

Staging and prognostic systems: beyond BCLC?

Staging and prognostic systems: beyond BCLC? Staging and prognostic systems: beyond BCLC? Alessandro Vitale, MD, PhD, FEBS U.O.C. di Chirurgia Epatobiliare e dei Trapianti Epatici, Department of Surgery, Oncology and Gastroenterology, University

More information

Changing epidemiology of HCC in Italy

Changing epidemiology of HCC in Italy Changing epidemiology of HCC in Italy G. Svegliati-Baroni Clinica di Gastroenterologia SOS Epatopatie Croniche-Trapianto di Fegato Università Politecnica delle Marche, Ancona Worldwide estimated new PLC

More information

HCV elimination : lessons from Scotland

HCV elimination : lessons from Scotland HCV elimination : lessons from Scotland Sharon Hutchinson Glasgow Caledonian University / Health Protection Scotland BHIVA Hepatology Highlights, Edinburgh, 17 th April 2018 Disclosures Honoraria from

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE Worldwide Causes of HCC 60% 50% 40% 54% 30% 20% 10% 31% 15% 0% Hepatitis B Hepatitis

More information

Towards Precision Medicine in Primary Biliary Cholangitis

Towards Precision Medicine in Primary Biliary Cholangitis Riunione Monotematica A.I.S.F. 2016 THE FUTURE OF LIVER DISEASES: Beyond HCV is there a role for the hepatologist? 14 th October 2016 Towards Precision Medicine in Primary Biliary Cholangitis Marco Carbone,

More information

The future of liver transplantation for viral hepatitis

The future of liver transplantation for viral hepatitis The future of liver transplantation for viral hepatitis François Durand Hepatology & Liver Intensive Care Hospital Beaujon, Clichy University Paris Diderot France Liver transplantation in France 2013:

More information

Riunione Monotematica AISF 2017 Roma 5 Ottobre Management of Alcohol Use Disorders in Patients with Alcoholic Liver Disease

Riunione Monotematica AISF 2017 Roma 5 Ottobre Management of Alcohol Use Disorders in Patients with Alcoholic Liver Disease Riunione Monotematica AISF 2017 Roma 5 Ottobre 2017 Management of Alcohol Use Disorders in Patients with Alcoholic Liver Disease Lorenzo Leggio, M.D., Ph.D., M.Sc. Lorenzo Leggio, M.D., Ph.D., M.Sc. Il

More information

Hepatocellular carcinoma: from guidelines to individualized treatment

Hepatocellular carcinoma: from guidelines to individualized treatment AISF 2012 Rome, 22-24 February 2012 Hepatocellular carcinoma: from guidelines to individualized treatment A.D. 1088 Luigi Bolondi Professor of Medicine, Chairman Department of Digestive Diseases and Internal

More information

Bariatric Surgery and Liver Transplantation

Bariatric Surgery and Liver Transplantation Bariatric Surgery and Liver Transplantation Sammy Saab, MD, MPH, AGAF, FACG, FAASLD Professor of Medicine and Surgery Head, Outcomes Research in Hepatology David Geffen School of Medicine at UCLA Disclosures

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice

3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice 3 Workshop on HCV THERAPY ADVANCES New Antivirals in Clinical Practice Rome, 13 December 2013 Management and monitoring of HCC in the future era of DAA s Prof. Massimo Colombo Chairman Department of Liver,

More information

Liver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York

Liver Pathology and the Clinician in 2015: At the Crossroads. Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York Liver Pathology and the Clinician in 2015: At the Crossroads Thomas D. Schiano, M.D. Mount Sinai Medical Center New York, New York DISCLOSURES Consultant for: Salix Merck Gilead BMS Synageva Research funding:

More information

The place of bariatric surgery in NASH: can we extend the indications? - No

The place of bariatric surgery in NASH: can we extend the indications? - No The place of bariatric surgery in NASH: can we extend the indications? - No Nicolas Goossens Service de Gastroentérologie & Hépatologie Hôpitaux Universitaires de Genève Genève, Suisse How to extend the

More information

Life After SVR for Cirrhotic HCV

Life After SVR for Cirrhotic HCV Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data

More information

Complication of Portal Hypertension: should the patients in the waiting list be treated differently?

Complication of Portal Hypertension: should the patients in the waiting list be treated differently? Wilma Debernardi Venon Gastroepatologia, Az. Osp. San Giovanni Battista ditorino Complication of Portal Hypertension: should the patients in the waiting list be treated differently? Il sottoscritto dichiara

More information

Worldwide Causes of HCC

Worldwide Causes of HCC Approach to HCV Treatment in Patients with HCC Mark W. Russo, MD, MPH, FACG Carolinas HealthCare System Charlotte Worldwide Causes of HCC 60% 50% 40% 30% 20% 10% 0% 54% 31% 15% Hepatitis B Hepatitis C

More information

Cirrhosis is different from Fibrosis

Cirrhosis is different from Fibrosis Riunione Monotematica AISF 2016 «The Future of Liver Disease: Beyond HCV is there a Role for Hepatologist» Milan 13 th -14 th 2016 Cirrhosis is different from Fibrosis I have not disclosures to declare

More information

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none

More information

Hepatocellular Carcinoma (HCC): Burden of Disease

Hepatocellular Carcinoma (HCC): Burden of Disease Hepatocellular Carcinoma (HCC): Burden of Disease Blaire E Burman, MD VM Hepatology Hepatocellular Carcinoma (HCC) Primary HCCs most often arise in the setting of chronic inflammation, liver damage, and

More information

BOCEPREVIR (BOC): EVIDENCE FROM TRIALS

BOCEPREVIR (BOC): EVIDENCE FROM TRIALS BOCEPREVIR (BOC): EVIDENCE FROM TRIALS ROME, FEBRUARY 22 nd -25 th, 212 Savino Bruno, MD Department of Internal Medicine A.O. Fatebenefratelli e Oftalmico Milan, Italy Savino Bruno, MD Director of InternalMedicine,

More information

The impact of the treatment of HCV in developing Hepatocellular Carcinoma

The impact of the treatment of HCV in developing Hepatocellular Carcinoma The impact of the treatment of HCV in developing Hepatocellular Carcinoma Paul Y Kwo, MD Professor of Medicine Medical Director, Liver Transplantation Gastroenterology/Hepatology Division Indiana University

More information

Hepatitis C Policy Discussion

Hepatitis C Policy Discussion Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany

Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:

More information

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)

Glecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,

More information

Liver Transplant: Alcoholic liver disease as first indication

Liver Transplant: Alcoholic liver disease as first indication Monotematica AISF The future of liver disease: beyond HCV there is a role for hepatologist? Milano, 13-15 Ottobre 2016 Liver Transplant: Alcoholic liver disease as first indication Giacomo Germani Multivisceral

More information

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di

More information

Perché viene la NASH (2): microbiota e permeabilità intestinale G. Svegliati-Baroni

Perché viene la NASH (2): microbiota e permeabilità intestinale G. Svegliati-Baroni Perché viene la NASH (2): microbiota e permeabilità intestinale G. Svegliati-Baroni Clinica di Gastroenterologia SOS Epatopatie Croniche e Trapianto di Fegato Università Politecnica delle Marche Ancona

More information

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA

Evaluating HIV Patient for Liver Transplantation. Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Evaluating HIV Patient for Liver Transplantation Marion G. Peters, MD Professor of Medicine University of California San Francisco USA Slide 2 ESLD and HIV Liver disease has become a major cause of death

More information

HIV coinfection and HCC

HIV coinfection and HCC HIV coinfection and HCC 3 rd APASL STC on HCC 21 st -23 rd Nov 2013 Cebu, Phillippines George KK Lau MBBS (HK), MRCP(UK), FHKCP, FHKAM (GI), MD(HK), FRCP (Edin, Lond) Consultant, Humanity and Health GI

More information

Hepatocellular Carcinoma: Epidemiology and Screening

Hepatocellular Carcinoma: Epidemiology and Screening Hepatocellular Carcinoma: Epidemiology and Screening W. Ray Kim, MD Professor and Chief Gastroenterology and Hepatology Stanford University School of Medicine Case A 67 year old Filipino-American woman

More information

Position Paper of the Italian Association for the Study of the Liver for the rational use of anti-hcv drugs available in Italy

Position Paper of the Italian Association for the Study of the Liver for the rational use of anti-hcv drugs available in Italy Position Paper of the Italian Association for the Study of the Liver for the rational use of anti-hcv drugs available in Italy Advisory committee on new drugs for Hepatitis C : Alessio Aghemo (Coordinator)

More information

DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC.

DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC. DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC. Robert J. de Knegt, Erasmus MC, Rotterdam r.deknegt@erasmusmc.nl Disclosures

More information

Liver Pathology in the 0bese

Liver Pathology in the 0bese Liver Pathology in the 0bese Rob Goldin Centre for Pathology, Imperial College r.goldin@imperial.ac.uk Ludwig et al. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

More information

Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States

Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States GASTROENTEROLOGY 2011;141:1249 1253 Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States MICHAEL R. CHARLTON,* JUSTIN M. BURNS, RACHEL A. PEDERSEN, KYMBERLY

More information

Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients

Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients Editorial Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients Nobuhisa Akamatsu, Junichi Togashi, Kiyoshi Hasegawa, Norihiro Kokudo Artificial Organ and Transplantation

More information

Hepatocellular Carcinoma: Can We Slow the Rising Incidence?

Hepatocellular Carcinoma: Can We Slow the Rising Incidence? Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline

More information

HCV Therapy in Liver Transplant Candidate

HCV Therapy in Liver Transplant Candidate PHC 216 HCV Therapy in Liver Professor Didier SAMUEL Transplant Candidate Dr Audrey COILLY Centre Hépato-Biliaire, Inserm 1193 Treat before orrearch afuniter? University Paris Sud A Villejuif u d r e yfrance

More information

First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health

First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st NAFLD/NASH : an expanding burden on liver health First European NAFLD-NASH Summit European Parliament, Brussels, May 31 st 2017 NAFLD/NASH : an expanding burden on liver health Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière,

More information

Should Elderly CHC Patients (>70 years old) be Treated?

Should Elderly CHC Patients (>70 years old) be Treated? Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,

More information

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic

More information

Bariatric Surgery For Patients With End-Organ Failure

Bariatric Surgery For Patients With End-Organ Failure Bariatric Surgery For Patients With End-Organ Failure Arnold D. Salzberg, M.D. Andrew M. Posselt, M.D., PhD Divisions of Transplant and Minimally Invasive Surgery University of California, San Francisco

More information

What s new in Hepatology AASLD 2016

What s new in Hepatology AASLD 2016 What s new in Hepatology AASLD 2016 CWN Spearman C Kassianides What s new in Hepatology? AASLD 2016 CWN SPEARMAN Hepatitis C Alcoholic liver disease Cholestatic Liver Disease Primary biliary Cholangitis

More information

Hepatocellular Carcinoma. Markus Heim Basel

Hepatocellular Carcinoma. Markus Heim Basel Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749

More information

HCV care after cure. This program is supported by educational grants from

HCV care after cure. This program is supported by educational grants from HCV care after cure This program is supported by educational grants from Raffaele Bruno,MD Department of Infectious Diseases, Hepatology Outpatients Unit University of Pavia Fondazione IRCCS Policlinico

More information

Case 1 AND. Treatment of HCV: Pre- vs Post- Transplant. 58 yo male, ESRD/diabetic nephropathy, HD for 3 weeks

Case 1 AND. Treatment of HCV: Pre- vs Post- Transplant. 58 yo male, ESRD/diabetic nephropathy, HD for 3 weeks Treatment of HCV: Pre- vs Post- Transplant Roy D. Bloom MD Professor of Medicine University of Pennsylvania Roy D. Bloom MD Professor of Medicine Medical Director, Kidney Transplant Program University

More information

Hepatocellular Carcinoma Surveillance

Hepatocellular Carcinoma Surveillance Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated

More information

Hepatitis C Policy Discussion

Hepatitis C Policy Discussion Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Umberto Volta Coeliac Disease and Malbsorption Unit Digestive Diseases and Internal Medicine Dept St.Orsola-Malpighi Hospital, Bologna

Umberto Volta Coeliac Disease and Malbsorption Unit Digestive Diseases and Internal Medicine Dept St.Orsola-Malpighi Hospital, Bologna Coeliac disease Umberto Volta Coeliac Disease and Malabsorption Unit Digestive Diseases and Internal Medicine Dept. St. Orsola-Malpighi Hospital University of Bologna President of the Scientific Board

More information

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology

More information

Screening for HCCwho,

Screening for HCCwho, Screening for HCCwho, how and how often? Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital HCC Global Epidemiology

More information

DAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France

DAA-based treatment in cirrhotic and post-transplanted patients. Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France DAA-based treatment in cirrhotic and post-transplanted patients Audrey Coilly, MD Hôpital Paul Brousse, Villejuif, France Cirrhosis and transplantation 2 populations with similar issues Hepatic impairment

More information

AASLD, Boston, USA, 10 th November 2014 [oral presentation]

AASLD, Boston, USA, 10 th November 2014 [oral presentation] Effects of Sustained Virological Response on the of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 34,563 patients with Hepatitis C infection. Andrew

More information

Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre

Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Chronic viral hepatitis and liver disease in Belgium Pierre Deltenre Brussels, November 7, 2017 Hepatitis B and C in Belgium What we need to know 1. Who is at risk of infection? 2. What is the natural

More information

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) NON-ALCOHOLIC STEATOHEPATITIS (NASH) ADDRESSING A GROWING SILENT EPIDEMIC NON-ALCOHOLIC FATTY LIVER DISEASE () & NON-ALCOHOLIC STEATOHEPATITIS () ADDRESSING A GROWING SILENT EPIDEMIC PREVALENCE OF / USA Prevalence in Middle Age Patients San Antonio, Texas (Williams et al., Gastroenterology

More information

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR

Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR Hepatitis Alert: Management of Patients With HCV Who Have Achieved SVR This program is supported by educational grants from AbbVie, Gilead Sciences, and Merck About These Slides Please feel free to use,

More information

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals

Liver Cancer: Epidemiology and Health Disparities. Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals Liver Cancer: Epidemiology and Health Disparities Andrea Goldstein NP, MS, MPH Scientific Director Onyx Pharmaceuticals 1. Bosch FX, et al. Gastroenterology. 2004;127(5 suppl 1):S5-S16. 2. American Cancer

More information

Viral hepatitis and Hepatocellular Carcinoma

Viral hepatitis and Hepatocellular Carcinoma Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline

More information

Antiviral treatment in HCV cirrhotic patients on waiting list

Antiviral treatment in HCV cirrhotic patients on waiting list Antiviral treatment in HCV cirrhotic patients on waiting list Krzysztof Tomasiewicz Department of Hepatology and Infectious Diseases Medical University of Lublin, Poland Disclosures Consultancy/Advisory

More information

NAFLD: The role of genetics

NAFLD: The role of genetics NAFLD: The role of genetics Luca Valenti Department of Pathophysiology and Transplantation, Università degli Studi di Milano Internal Medicine, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

More information

Appendix Table A Frequency of end-stage liver disease in inception cohort. Reference Exposure followup Frequency ESLD (%) Seeff-1 PTH 24 23/568 (4%) 7

Appendix Table A Frequency of end-stage liver disease in inception cohort. Reference Exposure followup Frequency ESLD (%) Seeff-1 PTH 24 23/568 (4%) 7 Published as supplied by the author Appendix Table A Frequency of end-stage liver disease in inception cohort studies Route of Years Reference Exposure followup Frequency ESLD (%) Locasciulli PTH 1 15

More information

Dr. Siddharth Srivastava

Dr. Siddharth Srivastava Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.

More information

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views

More information

Liver transplantation and hepatitis C virus

Liver transplantation and hepatitis C virus Liver transplantation and hepatitis C virus Where do we come from? Where are we? Where are we going? François Durand Hépatologie & Réanimation Hépato-Digestive INSERM U1149 Hôpital Beaujon, Clichy HCV:

More information

Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;

Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Editorial The unexpected high risk of occurrence or recurrence of hepatocellular carcinoma after successful antiviral therapy with interferon-free direct-acting antivirals Ming-Lung Yu 1,2,3, Chung-Feng

More information

Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France

Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France 9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures

More information

Liver Transplantation: The End of the Road in Chronic Hepatitis C Infection

Liver Transplantation: The End of the Road in Chronic Hepatitis C Infection University of Massachusetts Medical School escholarship@umms UMass Center for Clinical and Translational Science Research Retreat 2012 UMass Center for Clinical and Translational Science Research Retreat

More information

Steatosi epatica ed HCV

Steatosi epatica ed HCV Steatosi epatica ed HCV Malattie delle vie biliari ed Epatologia Rho, Auditorium Padri Oblati, 11 Novembre 2006 Piero L. Almasio Università di Palermo HISTOPATHOLOGY Steatosis and accelerated fibrogenesis:

More information

Transplantation. Professor Didier. Centre Hépatobiliaire, Hépatobiliaire, C.H.B.

Transplantation. Professor Didier. Centre Hépatobiliaire, Hépatobiliaire, C.H.B. Treatment Treatment of of Hepatitis Hepatitis C C in in Liver Liver Transplantation Transplantation Professor Professor Didier Didier Samuel Samuel Centre Centre Hépatobiliaire, Hépatobiliaire, Inserm

More information

AASLD Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital

AASLD Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital AASLD 2017 - Washington DC, USA Dr. Alexander Kim Chief Vascular and Interventional Radiology, Medstar Georgetown University Hospital THE CHANGING LANDSCAPE IN THE TREATMENT OF HCC DISCLAIMER Please note:

More information

Personalizzazione della Cura in Epatologia. Epatite Cronica C: Pazienti con Genotipo 2

Personalizzazione della Cura in Epatologia. Epatite Cronica C: Pazienti con Genotipo 2 Monotematica AISF 213 Personalizzazione della Cura in Epatologia Pisa, 17-19 Ottobre 213 Epatite Cronica C: Pazienti con Genotipo 2 Maria Grazia Rumi U.O. Epatologia, Ospedale San Giuseppe Università degli

More information

9th Paris Hepatitis Conference

9th Paris Hepatitis Conference 9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units

More information

Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London

Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London Fatty Liver- how important is it? Jeremy F.L. Cobbold MA PhD MRCP Clinical Lecturer in Hepatology Imperial College London Fatty liver- how important is it? Importance in terms of: Prevalence Pathogenesis

More information

IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE?

IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? IL TRAPIANTO DI FEGATO: QUALE FUTURO CON LE NUOVE TERAPIE PER LE MALATTIE EPATICHE? Francesco Paolo Russo Department of Surgery, Oncology and Gastroenterology Multivisceral/ Gastroenterology Section University

More information

THE CHANGING LANDSCAPE OF HEPATITIS INFECTION. Michael E. Herman D.O.

THE CHANGING LANDSCAPE OF HEPATITIS INFECTION. Michael E. Herman D.O. THE CHANGING LANDSCAPE OF HEPATITIS INFECTION Michael E. Herman D.O. What s New? For Primary Care Providers Importance of diagnosing HCV For HCV Treaters How can we improve current therapies? For everyone

More information

METABOLIC SYNDROME AND HCV: FROM HCV

METABOLIC SYNDROME AND HCV: FROM HCV METABOLIC SYNDROME AND HCV: FROM THEORY TO PRACTICE HCV Steatosis Insulin resistance Arun J Sanyal M.D. Chairman, Div. of Gastroenterology, Hepatology and Nutrition Virginia Commonwealth University Richmond,

More information

Healthy Liver Cirrhosis

Healthy Liver Cirrhosis Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The

More information

Autoimmune Hepatitis Events Easl

Autoimmune Hepatitis Events Easl Autoimmune Hepatitis Events Easl 1 / 6 2 / 6 3 / 6 Autoimmune Hepatitis Events Easl INTRODUCTION. Autoimmune hepatitis is a chronic, inflammatory disease of the liver that is characterized by circulating

More information

Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus

Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL

More information

Management of Chronic HCV 2017 and Beyond

Management of Chronic HCV 2017 and Beyond Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence

More information

The Disease Burden of Hepatitis C in Belgium : development of a realistic disease control strategy

The Disease Burden of Hepatitis C in Belgium : development of a realistic disease control strategy 280 POSITION PAPER : BELGIAN WORKING GROUP FOR HEPATITIS C The Disease Burden of Hepatitis C in Belgium : development of a realistic disease control strategy P. Stärkel 1, D. Vandijck 2,3, W. Laleman 4,

More information

ANTIVIRAL THERAPY FOR HCV. Alfredo Alberti

ANTIVIRAL THERAPY FOR HCV. Alfredo Alberti CLINICAL IMPACT OF SVR AFTER ANTIVIRAL THERAPY FOR HCV Alfredo Alberti Department of Histology,Microbiology and Medical Biotechnologies Molecular Hepatology Unit Venetian Institute of Molecular Medicine

More information

Liver disease in 2017: challenges and opportunities

Liver disease in 2017: challenges and opportunities Liver disease in 2017: challenges and opportunities Dr Matthew Cowan Consultant Gastroenterologist and Hepatologist Surrey and Sussex Healthcare NHS Trust Faculty of Physician Associates 2 nd National

More information

Why make this statement?

Why make this statement? HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed

More information

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary

More information

Metabolic Syndrome and HCC. Jacob George

Metabolic Syndrome and HCC. Jacob George Metabolic Syndrome and HCC Jacob George MetS and risk of HCC and ICC All with HCC and ICC between 1993 and 2005 identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. For

More information

HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS

HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS HEPAMAP: A ROADMAP FOR HEPATOLOGY RESEARCH IN EUROPE: AN OVERVIEW FOR POLICY MAKERS HEPAMAP: A Roadmap For Hepatology Research In Europe: An Overview For Policy Makers Liver diseases are extremely costly

More information

HEPATOCELLULAR CARCINOMA: AN OVERVIEW

HEPATOCELLULAR CARCINOMA: AN OVERVIEW HEPATOCELLULAR CARCINOMA: AN OVERVIEW John K. Olynyk Head, Department of Gastroenterology & Hepatology Fiona Stanley Fremantle Hospital Group Dean of Research, Edith Cowan University RISING MORTALITY OF

More information